Brief: NANOBIOTIX Announces Recommended Phase 2 Dose For NBTXR3 In Pancreatic Cancer
14/11/2022 21:59
Nov 14 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES RECOMMENDED PHASE 2 DOSE FOR NBTXR3
IN
PANCREATIC CANCER
* NANOBIOTIX SA - EXPECTS TO REPORT SAFETY AND EARLY
EFFICACY DATA
FROM ESCALATION PART OF STUDY AT A MEDICAL CONGRESS IN 2023
Source text for Eikon: ID:nGNX3VLPXY
Further company coverage: NANOB.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering